CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943134940
- Phone
- 4154825300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- 4 Open-market sale SVP & Chief Accounting Officer sold 2,363 shares at $10.95 ($25,875)
- 4 Open-market sale President & CEO sold 12,480 shares at $10.95 ($136,656)
- 4 Open-market sale SVP & Chief Commercial Officer sold 4,852 shares at $10.95 ($53,129)
- 4 Open-market sale SVP, COO & CFO sold 7,579 shares at $10.95 ($82,990)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Results of operations · Regulation FD disclosure
- SC 13G/A Stake Amended Statement of Ownership
- 4 Grant or award Chief R&D Officer acquired 52,950 shares (grant or award)
- 4 Grant or award SVP & General Counsel acquired 37,800 shares (grant or award)
- 4 Grant or award SVP & Chief Accounting Officer acquired 21,200 shares (grant or award)
- 4 Grant or award President & CEO acquired 126,050 shares (grant or award)
- 4 Grant or award SVP & Chief Commercial Officer acquired 37,800 shares (grant or award)
- 4 Grant or award SVP, COO & CFO acquired 52,950 shares (grant or award)
- 4/A Insider Changes in Ownership
- UPLOAD Other SEC-generated Letter
Page 19 of 100 · 1,982 filings